Product IntroductionBioactivity英文名:
Bisacodyl描述: Bisacodyl (Fenilaxan) 是刺激性缓泻剂,可直接作用于结肠以产生排便。它能够直接激活结肠巨噬细胞来增加 PGE2的分泌。PGE2充当旁分泌因子并减少结肠中 AQP3 的表达,抑制水从腔向血管一侧的转移,进而产生通便作用。
体外活性: Bisacodyl抑制大鼠空肠,回肠和结肠的水分吸收,抑制程度与bisacodyl浓度的对数线性相关.4.3 mg/kg Bisacodyl与AOM联用增加大鼠体内每个集落小囊的数量,但是不增加肿瘤的数量.43 mg/kg Bisacodyl明显增加大鼠每个集落小囊和肿瘤的数量.与生理盐水处理的大鼠相比,Bisacodyl(5.9 mg/kg)显著降低空肠和结肠(Na + K)ATP酶活性.5.9 mg/kg Bisacodyl与对照组大鼠相比,明显增加空肠和结肠中PGE2含量,并刺激空肠和结肠腺苷酸环化酶的活性,且不影响cAMP含量.灌胃10 mg/kg Bisacodyl引起大鼠空肠NOS活性明显下降.20 mg/kg Bisacodyl导致大鼠结肠中AQP3蛋白质表达减少,而TNF-α的mRNA表达水平增加.
体内活性: 10 μg/mL Bisacodyl作用于Raw264.7细胞,增加TNF-α,COX2和PGE2的mRNA表达水平。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 67 mg/mL (185.4 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字:
Inhibitor |
Opioid Receptor |
Dopamine Transporter |
DAT |
Bisacodyl |
inhibit |
SLC6A3相关库:
FDA-Approved Drug Library |
Drug Repurposing Compound Library |
ReFRAME Related Library |
FDA-Approved & Pharmacopeia Drug Library |
Clinical Compound Library |
Anti-Metabolism Disease Compound Library |
Bioactive Compounds Library Max |
Orally Active Compound Library |
NO PAINS Compound Library |
Bioactive Compound Library